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relevant cost driver (69% of the total costs) followed by
diagnostic procedures (10%). The duration of the stay in
hospital is the decisive factor for the costs of inpatient
care from TPP’s perspective in Germany. The average
hospitalization length was 19.5 days. Assuming a hospi-
talization rate of 10% the direct medical costs per cp pa-
tient and year were 4,488 DM. CONCLUSION: It could
be shown that treatment of chronic polyarthritis is as
cost-intensive as other chronic diseases. Because of the
growing interest in the development of new concepts of
patient care (e.g. disease management), further cost and
outcome data should be assessed to show the relative
value for money (e.g. with cost-effectiveness analysis) in
order to guarantee an appropriate allocation of resources.
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COX-II INHIBITORS AND NSAIDS: FINDINGS OF 
A NICE SUBMISSION
Dickson AJ
Consultant Health Economist, c/o Primary Care Rheumatology 
Society, Northallerton, N. Yorkshire, UK
The National Institute of Clinical Excellence (NICE) is
conducting an appraisal of the new COX-II specific in-
hibitors (celecoxib and rofecoxib). NICE asked the Pri-
mary Care Rheumatology (PCR) society to comment on
the ‘real-life’ clinical and cost-effectiveness of the COX-II
specific inhibitors against NSAIDs and the COX-II selec-
tive inhibitors (etodolac and meloxicam) in the treatment
of arthritis. This poster summarises the findings of the
PCR’s NICE submission. OBJECTIVES: To use evi-
dence-based medicine to compare the ‘real-life’ clinical
and cost-effectiveness of the COX-II specifics versus
NSAIDs and the COX-II selectives, in the treatment of
arthritis and prevention of drug-related gastro-intestinal
(GI) adverse events in primary-care. METHODS: Using
PubMed, a literature review of NSAIDs, COX-II inhibi-
tors (celecoxib, etodolac, meloxicam and rofecoxib) and
‘best-practice’ guidelines in the treatment of arthritis was
undertaken. The review concentrated on the problems of
NSAID-related GI adverse events, their associated treat-
ment costs and whether COX-II inhibitors provide alter-
native, clinically and cost-effective methods of treating
arthritis. RESULTS: NSAID-related GI risk rises signifi-
cantly with patient age. In the UK, NSAID-related deaths
average 2,600 patients annually. The mean, NHS cost of
NSAID-related, GI adverse events is an extra £48 per
NSAID patient per year. COX-II specifics have signifi-
cantly better GI tolerability to NSAIDs. But COX-II spe-
cifics cost the NHS an extra £40.15 minimum annually
for the average NSAID patient. COX-II selectives are
cheaper than COX-II specifics and have significantly higher
GI tolerability than NSAIDs. CONCLUSIONS: COX-II
inhibitors represent a more clinically effective solution
for treating arthritis and reducing GI adverse events in
primary care than NSAIDs. There is a lack of ‘real-life ev-
idence’ to determine for which at risk patients COX-II
specifics are cost-effective over the COX-II selectives and
NSAIDs. Best-practice guidelines support the view that
there is a role for COX-II specifics, COX-II selectives and
NSAIDs in treating arthritis in primary care.
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THE COSTS OF RHEUMATOID ARTHRITIS:
IS THERE A NEED FOR STANDARDIZATION
OF METHODS?
Barbieri M, Drummond M
Centre for Health Economics, University of York, York, UK
OBJECTIVE: To summarise the state of knowledge in
terms of economic impact of rheumatoid arthritis (RA), to
highlight the level of aggregation of categories of costs in
different economic evaluations and to identify the burden
of productivity costs in RA. METHODS: Several comput-
erised databases (Medline, Embase, Econlit, OHE HEED,
NHS EED) were searched to identify the relevant studies
for the review. Among the hundreds of records found, 18
were selected for the analysis. The majority of them were
cost of illness studies. At the first stage three main catego-
ries of costs were considered (medical direct costs, non-
medical direct costs, productivity costs) and the economic
impact of each category was quantified. Then subcatego-
ries of costs were investigated in order to assess the grade
of homogeneity in the level of aggregation among differ-
ent studies. RESULTS: Direct medical costs were included
in every study. Total average direct medical costs were in
the range of US$6000 per year (per patient). Among
them, hospital costs constituted in general the largest
amount (from 25 to 40%) followed by medications and
arthritis professional visits. There was considerable lack
of homogeneity in the assessment of cost categories.
Many studies showed a skewed distribution of costs
among patients in relation to their level of severity. Non-
medical direct costs were in general not substantial. By
contrast the economic impact of indirect costs has re-
sulted extremely high, ranging from 1 to 3–4 times the di-
rect costs. Productivity costs are likely to be underesti-
mated given the difficulty of assessing the costs associated
with premature mortality. CONCLUSION: The literature
review indicated a strong need for a standardization in the
assessment of relevant costs for RA. Although there were
differences in the level of aggregation, all studies reported
productivity costs to be the largest category. New drugs
with the ability to reduce the long-term consequences of
RA are likely to have a significant economic impact.
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OBJECTIVE: To generate estimates of the potential number
of patients with rheumatoid arthritis (RA), who are con-
sidered candidates for etanercept in the Dutch health care
setting in order to allow an assessment of the impact of
etanercept on the annual drug budget. METHODS: A lit-
erature search on incidence and prevalence data for RA
was performed on international and Dutch literature. A
subsequent expert panel was used to 1) reach consensus
on epidemiological data to be used for the budgetary im-
pact analysis in The Netherlands, 2) validate the findings
of the literature, 3) give estimates, where we did not find
reliable data in the literature. This panel was a represen-
tative sample of Dutch rheumatologists. The budgetary
impact analysis was performed from the perspective of
the Ministry of Health. RESULTS: The total number of
registered adult patients being treated by rheumatologists
was based on a Diagnosis-Registration System (range:
30,000–60,000). The panel estimated that 98% of the
patients will receive medication (range: 29,400–58,800) and
that 7% of those patients are candidates for etanercept
(range: 2,058–4,116). The total cost for etanercept is be-
tween NLG 64,084,000 (EURO 29,080,051) and NLG
128,169,000 (EURO 58,160,557), which is based on a
twice weekly injection of NLG 299.42 (EURO 135.87).
The expected costs are between NLG 49,265,000 (EURO
22,355,482) and NLG 98,530,000 (EURO 44,710,965),
when incorporating preliminary treatment termination
and switching to a once weekly dosage. CONCLUSION:
The use of literature and an expert panel allowed us to
make a budgetary impact analysis for etanercept, which
contributed to obtaining reimbursement.
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COST-OF-ILLNESS STUDIES IN GERMANY WITH 
OSTEOPOROSIS AS EXAMPLE
Brecht JG, Schädlich PK
PAREXEL GmbH InForMed Outcomes Research & 
Pharmacoeconomics, Berlin, Germany
OBJECTIVES: To investigate the suitability of data sources
in Germany for methodologically sound and comprehen-
sive cost-of-illness studies and to demonstrate this by using
appropriate data sources to quantify the cost of illness
imposed by osteoporosis from the societal perspective.
METHODS: Secondary analysis of official and administra-
tive statistics, of structural data and of relevant publica-
tions was used to evaluate their appropriateness to estimate
direct and indirect cost incurred by osteoporosis and its se-
quelae. RESULTS: Suitable statistics are available in Ger-
many relating to the corresponding positions of the Inter-
national Classification of Diseases, 9th edition (ICD-9).
These statistics mostly cover resource use and days off
work, for example, rather than immediate costs, which can
be calculated using an adequate cost factor such as cost per
treatment day in hospital. In some cases, costs are given di-
rectly, as is the case with rehabilitation and long-term care
statistics, for example. The total annual direct and indirect
costs of osteoporosis and related fractures amounted to 4.3
billion DM in 1997. Direct costs for treatment of fractures
were corrected for non-osteoporotic causes; indirect costs
incurred by loss of productivity were discounted by 5% an-
nually. The largest part of 58% was caused by treatment in
acute hospitals and rehabilitation units. Further 15% of to-
tal costs were devoted to long-term nursing care and 13%
to outpatient care. Indirect costs due to inability to work,
early retirement and premature mortality amounted to
15% of total costs and were relatively low as compared to
other chronic diseases. CONCLUSIONS: (1) About three
quarter of the considerable costs imposed by osteoporosis
were devoted to late complications whereas cost for pre-
vention and rehabilitation were low. (2) Cost of illness can
be estimated in Germany for most of the diseases that are
classified on the 3-digit level of the ICD-9.
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Approximately 700,000 vertebral fractures occur annu-
ally in the US. However, vertebral fractures are perceived
as being inexpensive. Previous acute care cost estimates
range from approximately $2,300–$6,000. OBJECTIVE:
To estimate the acute care costs and resource intensity of
vertebral fractures in women. METHODS: The Nation-
wide Inpatient Sample (NIS) database was used to iden-
tify all admissions due to vertebral fracture (closed only,
without spinal injury: pathologic, cervical, thoracic, lum-
bar, unspecified; ICD-9 codes 733.13, 805.0x, 805.2x,
805.4x, 805.4x, 805.8x). Cases were excluded if charges
	$30,000. The NIS includes random samples of hospital
discharge abstracts across all payers from 22 states in the
US from 1997. Sampling weights were applied to create
national estimates. Charges, length-of-stay (LOS) and dis-
charge disposition were analyzed by age group. RE-
SULTS: In 1997, there were 57,807 hospital admissions
for vertebral fractures in women. Mean charges and LOS
were $8,082 and 5.7 days, respectively. Over one-third
were discharged to long-term care (LTC), another 29.4%
required other follow-up care. Patients aged 75 had
longer LOS and used more post-acute care compared to
younger patients. Overall, LOS and post-acute care for
vertebral fractures are slightly below that of hip fractures
(6.8 LOS, 49% LTC, 34% other follow-up care) and
higher versus all other types of fractures (4.9 LOS, 28%
LTC, 26% other care). CONCLUSIONS: This study sug-
gests that vertebral fractures are more expensive and re-
source intensive than previously reported. Furthermore,
